Evidence map›Paper›PMID 40084346›Full record

ArticleClinical parkinsonism & related disorders2025

Comparative safety of istradefylline in Parkinson's disease: A systematic review of randomized controlled trials and real-world studies.

Sagari Betté, Joyce Qian, Hannah Cummings, Hiroo Shimoda, Katsumi Shinoda, Ashley Thai, Sarah Batson, Gabrielle Redhead, Alexander Hodkinson, Daniel Truong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sagari BettéParkinson's Disease and Movement Disorders Center of Boca Raton, 951 NW 13th St, Suite 5E, Boca Raton, FL 33486, USA.
Joyce QianKyowa Kirin, Inc., 510 Carnegie Center, Suite 600, Princeton, NJ 08540, USA.
Hannah CummingsKyowa Kirin, Inc., 510 Carnegie Center, Suite 600, Princeton, NJ 08540, USA.
Hiroo ShimodaKyowa Kirin Co., Ltd., Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan.
Katsumi ShinodaKyowa Kirin Co., Ltd., Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan.
Ashley ThaiKyowa Kirin, Inc., 510 Carnegie Center, Suite 600, Princeton, NJ 08540, USA.
Sarah BatsonMtech Access, Rowood House, Murdock Road, Bicester, Oxfordshire, OX26 4PP, UK.
Gabrielle RedheadMtech Access, Rowood House, Murdock Road, Bicester, Oxfordshire, OX26 4PP, UK.
Alexander HodkinsonMtech Access, Rowood House, Murdock Road, Bicester, Oxfordshire, OX26 4PP, UK.
Daniel TruongThe Truong Neuroscience Institute, 9940 Talbert Ave., #100, Fountain Valley, CA 92708, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Istradefylline offers a novel mechanism (adenosine A Methods: A systematic review and Bayesian network Results: 100 RCTs and 55 RWE publications were identified; 76 RCTs were included in NMAs. Istradefylline demonstrated lower odds of serious AEs (odds ratio [OR] = 0.56; 95 % CrI: 0.32, 0.99), treatment-emergent AEs (0.43; 0.25, 0.73), treatment-related AEs (0.33; 0.19, 0.56), hallucinations (0.25; 0.06, 0.97), and withdrawal due to AEs (0.37; 0.19, 0.68) versus amantadine. Istradefylline showed lower odds of dyskinesia (0.63; 0.41, 0.99) and hypotension (0.19; 0.03, 0.82) versus catechol- Conclusion: Istradefylline exhibits a favorable safety profile versus other PD adjuncts, as demonstrated by RCTs and RWE.

Indexed as

Adjunctive therapiesComparative safetyNetwork meta-analysisParkinson’s diseaseSystematic literature review

Identifiers

PMID40084346
PMCPMC11904592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.